EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis

Maria-Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, Diana Aguiar de Sousa iD, Mira Katan, Lina Palaiodimou iD, Aristeidis H Katsanos iD, Ioanna Koutroulou, Vaia Lambadiari, Robin Lemmens, Sotirios Giannopoulos iD, Andrei V Alexandrov und 2 weitere

European Stroke Journal · 01.09.2024 · 9 (3) · 530-539

DOI: 10.1177/23969873241234238 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Stroke Journal, erschienen am 01.09.2024. Verfasst von Maria-Ioanna Stefanou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Stroke, Cardiovascular Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mounting evidence suggests that glucagon-like-peptide-1 receptor-agonists (GLP-1 RAs) attenuate cardiovascular-risk in type-2 diabetes (T2DM). Tirzepatide is the first-in-class, dual glucose-dependent-insulinotropic-polypeptide GIP/GLP-1 RA approved for T2DM. Patients and methods: A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs) was performed to estimate: (i) the incidence of major adverse cardiovascular events (MACE); and (ii) incidence of stroke, fatal, and nonfatal stroke in T2DM-patients treated with GLP-1 or GIP/GLP-1 RAs (vs placebo).

Results

Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included. Compared to placebo, GLP-1RAs or GIP/GLP-1 RAs reduced MACE (OR: 0.87; 95% CI: 0.81–0.94; p < 0.01; I 2 = 37%), all-cause mortality (OR: 0.88; 95% CI: 0.82–0.96; p < 0.01; I 2 = 21%) and cardiovascular-mortality (OR: 0.88; 95% CI: 0.80–0.96; p < 0.01; I 2 = 14%), without differences between GLP-1 versus GIP/GLP-1 RAs. Additionally, GLP-1 RAs reduced the odds of stroke (OR: 0.84; 95% CI: 0.76–0.93; p < 0.01; I 2 = 0%) and nonfatal stroke (OR: 0.85; 95% CI: 0.76–0.94; p < 0.01; I 2 = 0%), whereas no association between fatal stroke and GLP-1RAs was uncovered (OR: 0.80; 95% CI: 0.61–1.05; p = 0.105; I 2 = 0%). In secondary analyses, GLP-1 RAs prevented ischemic stroke (OR: 0.74; 95% CI: 0.61–0.91; p < 0.01; I 2 = 0%) and MACE-recurrence, but not hemorrhagic stroke (OR: 0.92; 95% CI: 0.51–1.66; p = 0.792; I 2 = 0%). There was no association between GLP-1RAs or GIP/GLP-1 RAs and fatal or nonfatal myocardial infarction. Discussion and conclusion: GLP-1 and GIP/GLP-1 RAs reduce cardiovascular-risk and mortality in T2DM. While there is solid evidence that GLP-1 RAs significantly attenuate the risk of ischemic stroke in T2DM, dedicated RCTs are needed to evaluate the efficacy of novel GIP/GLP-1 RAs for primary and secondary stroke prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2StrokeCardiovascular DiseasesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansRandomized Controlled Trials as TopicReceptors, Gastrointestinal HormoneGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorTirzepatide

Stichwörter der Autor:innen

GIP/GLP-1 receptor agonistGLP-1MACEstroketirzepatide

Substanzen

Hypoglycemic AgentsTirzepatidegastric inhibitory polypeptide receptorReceptors, Gastrointestinal HormoneGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
  • Stroke Center, Centro Hospitalar Universitário Lisboa Central and Institute of Anatomy, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Division of Neurology, McMaster University/Population Health Research Institute, Hamilton, ON, Canada.
  • Second Department of Neurology, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital, Thessaloniki, Greece.

ORCID-Profile: Diana Aguiar de Sousa, Lina Palaiodimou, Aristeidis H Katsanos, Sotirios Giannopoulos, Georgios Tsivgoulis

Zitieren

APA

Stefanou, M. I., Theodorou, A., Malhotra, K., Aguiar de Sousa, D., Katan, M., Palaiodimou, L., Katsanos, A. H., Koutroulou, I., Lambadiari, V., Lemmens, R., Giannopoulos, S., Alexandrov, A. V., Siasos, G., & Tsivgoulis, G. (2024). Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. European Stroke Journal. https://doi.org/10.1177/23969873241234238

Vancouver

Stefanou MI, Theodorou A, Malhotra K, Aguiar de Sousa D, Katan M, Palaiodimou L, et al. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. European Stroke Journal. 2024. doi:10.1177/23969873241234238

BibTeX
@article{Stefanou2024,
  author = {Stefanou, Maria-Ioanna and Theodorou, Aikaterini and Malhotra, Konark and Aguiar de Sousa, Diana and Katan, Mira and Palaiodimou, Lina and Katsanos, Aristeidis H and Koutroulou, Ioanna and Lambadiari, Vaia and Lemmens, Robin and Giannopoulos, Sotirios and Alexandrov, Andrei V and Siasos, Gerasimos and Tsivgoulis, Georgios},
  title = {Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis},
  journal = {European Stroke Journal},
  year = {2024},
  doi = {10.1177/23969873241234238}
}
Kostenlos starten →